<DOC>
	<DOCNO>NCT01229644</DOCNO>
	<brief_summary>The purpose study evaluate antitumor efficacy crenolanib ( CP-868,596 ) patient recurrent high grade glioma patient low grade glioma .</brief_summary>
	<brief_title>A Phase II Study Crenolanib ( CP-868,596 ) , Selective Potent Inhibitor PDGFR , Treatment Adult Gliomas</brief_title>
	<detailed_description>This Phase II study design evaluate antitumor efficacy crenolanib ( CP-868,596 ) patient recurrent high grade glioma patient low grade glioma . Concurrently , pharmacokinetics , tumor penetration ability crenolanib ( CP-868,596 ) inhibit PDGFR signaling evaluate give neo-adjuvant therapy patient radiographic evidence malignant glioma prior initial surgery . The study enroll 3 different cohort patient parallel . Cohort A enroll patient schedule undergo craniotomy resection newly diagnose glioma ( low high grade ) . Patients cohort A treated crenolanib ( CP-868,596 ) ( 300mg daily , empty stomach ) neo-adjuvant set minimum 3 day prior surgical resection tumor mass . Twelve patient accrue neo-adjuvant cohort allow u assess ability crenolanib ( CP-868,596 ) penetrate tumor , grade 3 4 glioma ( anaplastic astrocytomas glioblastoma ) leaky BBB , also grade 2 glioma ( low grade glioma ) tend intact blood-brain barrier ( BBB ) . Pharmacokinetic , pharmacodynamic biological assessment conduct tissue sample ( plasma brain tissue ) obtain patient , feasible . Cohorts B C enroll patient recurrent high grade glioma biopsy proven low grade glioma , respectively , residual measurable disease . Patients cohorts B C treat crenolanib ( CP-868,596 ) ( 300mg daily empty stomach ) continuously fulfill one criterion study discontinuation . Magnetic resonance imaging ( MRI ) do assess tumor response well progression free survival ( PFS ) . The primary endpoint cohort B C overall response rate accord Response Evaluation Criteria In Solid Tumors ( RECIST ) , assessed standard image modality . In addition , 6-month Progression-free survival ( cohort B ) 1-year PFS also assess .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<criteria>Male female , racial ethnic group Age 18 year old Patient able willing provide inform consent Adequate kidney liver function Karnofsky Performance Status â‰¥ 70 % Negative serum pregnancy test child bear potential terminate surgery , radiation , menopause current use two approve method birth control Imaging suggestive malignant glioma ( Cohort A ) History glioma measurable disease MRI ( Cohorts B C ) Histologically confirm GBM radiographic progression ( Cohort B ) . These patient permit prior therapy include surgery , radiation , Temozolomide , irinotecan bevacizumab . Histological confirmation lowgrade glioma ( Cohort C ) Patient unable provide inform consent ( comatose markedly cognitively impaired ) Female participant pregnant breastfeed Any concurrent anticancer therapy Karnofsky Performance status &lt; 70 % Any concurrent investigational agent within 4 week start study drug Patients liver disease ( know active Hepatitis B C ; steatohepatitis ; cirrhosis ) Hepatic : Bilirubin great 1x upper limit normal Transaminases great 1x upper limit normal Abnormal renal function Serum creatinine &gt; 1.7 ng/dl Patients concomitant medication induce inhibit CYP450 , enzyme induce antiepileptic drug ( EIAEDs ) ( Appendix III ) troglitazone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Recurrent glioma</keyword>
	<keyword>Low grade glioma</keyword>
	<keyword>PDGFR Inhibitor</keyword>
	<keyword>Crenolanib ( CP-868,596 )</keyword>
	<keyword>Neo-adjuvant Therapy</keyword>
</DOC>